Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
19 studies found for:    vical
Show Display Options
Rank Status Study
1 Active, not recruiting Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi
Conditions: Aspergillosis;   Invasive Fungal Infections
Intervention: Drug: isavuconazole
2 Completed A Trial to Evaluate the Safety of Intratumoral VCL-IM01 Followed by Electroporation in Metastatic Melanoma
Condition: Metastatic Melanoma
Intervention: Genetic: VCL-IM01 (encoding IL-2) with Electroporation
3 Completed Gene Therapy in Treating Patients With Stage III or Stage IV Melanoma
Conditions: Stage IV Melanoma;   Stage III Melanoma;   Recurrent Melanoma
Intervention: Drug: allovectin-7
4 Completed A Phase 3 Pivotal Trial Comparing Allovectin-7® Alone vs Chemotherapy Alone in Patients With Stage 3 or Stage 4 Melanoma
Condition: Metastatic Melanoma
Interventions: Biological: Allovectin-7®;   Drug: Dacarbazine (DTIC);   Drug: Temozolomide (TMZ)
5 Completed Chemotherapy With or Without Immunotherapy in Treating Patients With Stage III or Stage IV Melanoma
Conditions: Stage IV Melanoma;   Stage III Melanoma;   Recurrent Melanoma
Interventions: Drug: allovectin-7;   Drug: allovectin-7/dacarbazine;   Drug: dacarbazine
6 Recruiting Safety and Efficacy Trial of DNA Vaccines to Treat Genital Herpes in Adults
Condition: Genital Herpes Simplex Type 2
Interventions: Biological: VCL-HB01;   Biological: VCL-HM01;   Biological: PBS
7 Completed Pandemic Influenza Plasmid DNA Vaccines (Needle)
Condition: Influenza
Interventions: Biological: VCL-IPT1;   Biological: VCL-IPM1;   Biological: PBS
8 Completed Pandemic Influenza Plasmid DNA Vaccines (Needle-Free)
Condition: Influenza
Interventions: Biological: VCL-IPM1;   Biological: VCL-IPT1;   Biological: PBS
9 Completed Cytomegalovirus (CMV) Vaccine in Donors and Recipients Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)
Conditions: Acute Lymphoblastic Leukemia;   Chronic Myelogenous Leukemia;   Acute Myelogenous Leukemia;   Hodgkin's Lymphoma;   Non-Hodgkin's Lymphoma;   Myelodysplastic Syndrome
Interventions: Biological: VCL-CB01;   Other: Phosphate-buffered Saline (PBS)
10 Terminated Leuvectin in Treating Patients With Locally Recurrent Prostate Cancer
Condition: Prostate Cancer
Intervention: Biological: Leuvectin
11 Completed Phase II Trial of Allovectin-7® for Head and Neck Cancer
Conditions: Head and Neck Cancer;   Squamous Cell Carcinoma of the Oral Cavity or Oropharynx;   Head and Neck Neoplasms;   Carcinoma of the Head and Neck
Intervention: Genetic: Allovectin-7®
12 Terminated Leuvectin Followed By Surgery in Treating Patients With Stage II or Stage III Prostate Cancer
Condition: Prostate Cancer
Intervention: Biological: Leuvectin
13 Completed Phase II Trial of Allovectin-7® for Metastatic Melanoma
Conditions: Melanoma;   Metastatic Melanoma;   Malignant Melanoma;   Skin Cancer
Intervention: Genetic: Allovectin-7®
14 Completed Trial of pDNA CMV Vaccine (VCL-CT02) Followed by Towne CMV Vaccine (Towne) Challenge
Condition: Cytomegalovirus Infection
Interventions: Biological: VCL CT02 pDNA vaccine;   Biological: Towne CMV vaccine
15 Recruiting An Evaluation of a Cytomegalovirus (CMV) Vaccine (ASP0113) in CMV-Seropositive and CMV-Seronegative Healthy Subjects and CMV-Seronegative Dialysis Patients
Conditions: Healthy Subjects;   Cytomegalovirus Infection;   Dialysis
Interventions: Drug: ASP0113;   Drug: Placebo
16 Recruiting A Study to Evaluate the Efficacy and Safety of a Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seronegative Kidney Transplant Recipients Receiving an Organ From a CMV-Seropositive Donor
Condition: Kidney Transplantation Cytomegalovirus (CMV) Negative Recipients
Interventions: Biological: ASP0113;   Drug: Placebo
17 Completed Phase 1 Trial of CMV Towne Vaccine in Subjects Previously Received VCL CT02 Vaccine ID or IM
Condition: Cytomegalovirus Infection
Intervention: Biological: Towne CMV vaccine
18 Recruiting A Study to Evaluate a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT)
Conditions: Cytomegalovirus (CMV)-Positive Recipients;   Allogeneic, Hematopoietic Cell Transplant (HCT)
Interventions: Biological: ASP0113;   Drug: Placebo
19 Active, not recruiting Evaluation of the Safety and the Ability of a DNA Vaccine to Protect Against Dengue Disease
Conditions: Dengue Disease;   Dengue Fever
Interventions: Biological: Tetravalent Dengue Vaccine (TVDV);   Biological: Tetravalent Dengue Vaccine (TVDV) with Vaxfectin® (low-dose);   Biological: Tetravalent Dengue Vaccine TVDV with Vaxfectin® (High Dose)

Indicates status has not been verified in more than two years